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Abstract
Along with surgery and chemotherapy, radiation therapy is an essential treat-
ment option for metastatic and primary tumors of the central nervous system. 
Radiation toxicity may be compartmentalized into three subcategories including 
acute toxicities, early-delayed and late delayed effects. Radiation induced toxicity 
spans from self-limiting fatigue to more serious delayed side effects of radione-
crosis. Stereotactic radiosurgery has recently emerged as a highly focused delivery 
method of tumoricidal irradiation with promising results compared to whole brain 
irradiation in many cases. Recognizing and understanding toxicity from cranial 
irradiation can help guide therapy as ever evolving new technologies develop within 
this integral component of cancer treatment.
Keywords: cranial irradiation, CNS toxicity, stereotactic radiosurgery, radionecrosis, 
radiation induced brain toxicity
1. Introduction
Treatment of central nervous system (CNS) tumors involves surgery, chemo-
therapy, radiation therapy, immunotherapy, or a combination of these modalities. 
Radiation therapy is a highly effect treatment that plays a role in the management 
of brain metastases, gliomas, primary central nervous system lymphomas, and 
meningiomas among other brain tumors.
Radiation toxicity can be divided into three subcategories including acute 
toxicities, usually arising within 6 weeks of treatment, early-delayed effects (up to 
4 months post-irradiation) and late delayed starting 4 months after completion of 
radiation therapy to several years later.
Central nervous system toxicity can be better understood by compartmental-
izing toxicities based on cell biology. Injury to brain parenchyma effected by 
radiation includes neuronal cells, glial cells, and vasculature. Surprisingly, side 
effects of radiation are likely not due to damage directly to neuronal cells [1]. This 
is in part due to the paucity of cell replication of most neurons. As such, radiation 
toxicity primarily effects glial oligodendrocytes which are the insulating myelin 
producing cells and glial astrocytes responsible for the essential blood brain bar-
rier. Endothelial vasculature of post-capillary venules within brain parenchyma are 
also highly susceptible to damaging effects of ionizing radiation. Increased cranial 
pressure and edema caused by radiation is deemed to be related to damage to endo-
thelial cells [2]. In addition to direct damage to the endothelia, the tight junctions of 
endothelial cells are another component of the blood-brain barrier. The saliency of 
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the blood brain barrier and the susceptibility to damage by irradiation, makes it a 
point of focus when discussing CNS toxicity.
Not all neuronal cells are uniformly resilient to ionizing radiation. Recent studies 
have shown extreme sensitivity to even low-dose irradiation to the hippocampus. 
This is due to damage to highly proliferative neuronal progenitor cells. Specifically, 
the subgranular zone (SGZ) of the dentate gyrus has been shown to be extremely 
susceptible to damage to progenitor cells. Research for why these phenomena exists is 
ongoing. In addition to direct damage to neural progenitor cells, recent studies have 
linked neuronal damage to endothelial vasculature within the SGZ. Loss of integrity 
of inter-endothelial tight junctions (and eventually the blood brain barrier) causes 
edema and an inflammatory response that prevents the proliferation of neuronal pro-
genitor cells. Clinical manifestations of impairment within this very crucial part of 
the CNS (the dentate gyrus of the hippocampus which is responsible for transition-
ing short term memories into long term memories) is linked to the irreversible late 
delayed side effect of cognitive dysfunction [3–5]. It is worth mentioning that these 
sequelae of radiation to the hippocampus can manifest even with doses as low as 2 Gy 
or less [6, 7]. Strategies to preserve neurocognitive function in patients receiving 
whole brain radiation therapy now include hippocampal sparing techniques [8, 9]. 
Hippocampal avoidance is one of many creative strategies postulated by radiation 
oncologists to aid in minimizing toxicity. Modern radiation delivery techniques are 
beyond the scope of this chapter. Some of these modalities used to avoid sensitive 
anatomic regions and decrease healthy tissue exposure include IMRT, stereotactic 
radiosurgery, and proton therapy. These novel modalities of radiation therapy con-
tinue to be refined in hopes of decreasing brain injury and increasing local control.
Astrocytes also play an important role in support and function of neurons. The 
cell line responsible for proliferation and differentiation of astrocytes and oligo-
dendrocytes is the oligodendrocyte type-2 astrocyte progenitor cell (O-2A) [2]. In 
addition to being a crucial component of the BBB, astrocytes have been shown to be 
homeostatic regulators providing multiple heterogeneous functions including pro-
tecting brain parenchyma from reactive oxygen species [10]. Neuroinflammation 
and reactive astrogliosis caused by irradiation to astrocytes and O-2A, disrupt the 
BBB and likely play a role in edema.
Therapeutic techniques investigating the loss of neurogenesis are also underway. 
Inflammation is primarily instigated by microglial cells. Decreasing the inflam-
matory load within the SGZ by using a nonsteroidal anti-inflammatory, namely 
indomethacin in this case, helped preserve neuronal progenitor cells [6]. Reducing 
the inflammatory load caused by radiation may decrease CNS toxicity which in this 
study was cognitive decline. Prophylactic nonsteroidal anti-inflammatory drugs are 
not currently standard of care in preventing radiation side effects.
As mentioned earlier, glial cells are by far the most abundant types of cells 
within the CNS and responsible for neuronal support and protection. Glial progeni-
tor cells which gives rise to oligodendrocytes and astrocytes are vulnerable targets 
of damage induced by radiation. In addition to glial progenitors, fully differentiated 
oligodendrocytes are also known to be sensitive to radiation. Enough damage to 
the DNA of oligodendrocytes can induce a P53 dependent apoptosis [2, 11]. Taking 
these two cell lines into consideration, damage to myelin producing oligodendro-
cytes in addition to glial progenitor cells responsible for generating new oligoden-
drocytes and astrocytes leads to CNS toxicity [2]. Treatment strategies to ameliorate 
CNS toxicity focused on re-establishing the efficacy of glial progenitor cells are 
ongoing. To date, optimal treatment for CNS toxicity is still unknown and strategies 
for managing side effects have yet to be delineated.
When considering the source of CNS toxicities, it is important to take into con-
sideration the timeframe of manifestations, the specific presentation of symptoms, 
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as well as whether the volume treated and dose deliver are compatible with side 
effects to the CNS. Other modalities of treatment including chemotherapy and 
immunotherapy as well as tumor progression can also have adverse effects on brain 
parenchyma on a cell biologic level. Deciphering the cause of CNS injury is not 
completely understood but should be taken into consideration in guiding treatment 
options.
2. Acute and early-delayed toxicities of cranial irradiation
Early side effects of radiation treatment are considered to manifest during or 
within 6 weeks of completion of radiation therapy. Acute side effects are usually 
transient and self-limiting, due to transient demyelination [3]. Symptoms are rare 
but may include fatigue, nausea, vomiting, headache, and focal neurologic deficits. 
These reported side effects were historically common with patients receiving doses 
>2 Gy per fraction. Reflected in current NCCN guidelines, most clinicians do not 
deliver conventional doses that exceed 2 Gy in one fraction as to avoid side effects. 
Acute radiation toxicities are rare with modern techniques with reports of grade 3 
and 4 acute toxicities occurring in <5% of patients and are usually self-limiting [12].
Side effects occurring within 4 months of radiation treatment are considered 
early delayed effects and most commonly involve transient demyelination and 
somnolence. Similar to acute toxicities, early to late side effects are usually revers-
ible and resolve spontaneously.
2.1 Fatigue
One of the most common side effect of radiation therapy to the central nervous 
system is fatigue and lethargy. Similar to patterns of irradiation outside of the CNS, 
side effects are cumulative and initially start to present 2 weeks into therapy [13, 14]. 
Fatigue usually starts around 2 weeks of therapy, peaks at or around completion 
of therapy, and resolves within several months. A severe form of fatigue, lethargy, 
and lack of concentration is known as somnolence syndrome (SS). SS typical occurs 
as an early delayed toxicity approximately 5–6 weeks after completion of radiation 
therapy. In one study, patients receiving a hypofractionated treatment plan com-
pared to conventional fractionation experienced more severe fatigue [15].
2.2 Alopecia and radiation dermatitis
Another common side effect of acute radiation toxicity is hair loss. Alopecia from 
radiation only occurs in areas where hair follicles are exposed to radiation and there-
fore can be sparse depending on scalp exposure. Alopecia can be permanent or tem-
porary with higher doses to the scalp signifying permanent hair loss [16]. Radiation 
dermatitis is a desquamating rash that can occur to areas of the scalp exposed to 
radiation. Most cases are mild and are treated with moisturizing ointments. In severe 
rare cases of moist desquamation, topical antibiotic ointment may be used.
3. Late-delayed toxicities of cranial irradiation
Late-delayed side effects are of the most concern when discussing radiation 
toxicity. These effects occur starting after 4 months of treatment up to decades 
later. Unlike acute and early-delayed side effects, late-delayed side effects are largely 
irreversible and progressive.
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3.1 Cumulative effects
Decline in neurocognitive function in patients with brain tumors is a multifacto-
rial phenomenon. The connection between radiation toxicity and cognitive decline 
has been well documented. Nevertheless, it is important, however, to consider 
other factors as well as cumulative effects contributing to cognitive decline. Many 
patients treated with radiation are also treated in combination with chemotherapy. 
Multiple new targeted therapies have also been approved for use. Given that each 
of these individually may cause CNS side effects, it is of utmost importance for 
healthcare providers to be able to recognize toxicity and delineate whether symp-
toms are indeed being caused by treatments (either in combination or individually). 
Furthermore, there are multiple other reasons for why patients may have CNS com-
plications, including tumor progression and advancement of pathologies unrelated 
to malignancy (dementia, depression, polypharmacy, anxiety, etc.).
3.2 Long term delayed effects
There exist patients who have undergone radiation treatment with an overall 
survival of multiple years and even decades. For many, cognitive deficits have 
not arisen even after 6 years of follow-up [6, 13]. Most patients even after 6 years 
have maintained a stable neurocognitive status. Differences in cognitive deficits 
were seen, however, in patients with low-grade gliomas who received radiation 
compared to patients who were radiation naïve after a 12 year follow up [6]. It is 
worth mentioning however that patients who do receive adjuvant radiation in low 
grade gliomas are more likely to have local control, better progression free survival 
and overall survival [14]. Multiple considerations should be taken into account 
when deciding the correct treatment plan for each individual patient. In the case 
of low grade gliomas, radiation and chemotherapy with procarbazine, CCNU, and 
vincristine is recommended by current NCCN guidelines. Given that neurocogni-
tive effects are being reported over a decade after radiation treatment and less so at 
6 years, additional long term delayed effects are of more trepidation now compared 
to years prior.
4. Stereotactic radiosurgery
Advances in the technique and technology of radiation treatment to the brain 
has given rise to stereotactic radiosurgery. The use of localized radiosurgery in the 
setting of metastatic disease compared to whole-brain radiotherapy is an ongo-
ing and complex discussion. In general, brain metastases arise from hematologic 
dissemination and have a poor overall prognosis [17]. Whole brain radiation has 
been utilized given the assumed likelihood of “seeding” or micrometasis to areas 
of the brain outside of visible metastasis seen on imaging. As mentioned earlier 
however, whole brain radiation therapy has high rates of toxicity, the most serious 
being cognitive impairment without the added benefit of overall survival [18–20]. It 
is worth mentioning that the concept of oligometastases has arisen among oncolo-
gists whereby disease may in fact be truly limited and treated as such. SRS alone, 
or in combination with whole brain radiation therapy, has thus become a viable 
option in single lesions or oligometastases. Being a localized modality of treatment, 
SRS alone has a higher likelihood of intracranial progression when compared with 
SRS in combination with WBRT. There has not been shown an increase in overall 
survival nor a better side effect profile with the addition WBRT to SRS vs. SRS 
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alone [19, 20]. Researchers have also concluded that the addition of WBRT results 
in excess morbidity and a decreased quality-of-life resulting in a 35% increase in 
neurocognitive deficit compared to SRS alone at 12 months. In one study, there was 
also a non-statistically significant survival benefit with SRS alone compared to SRS 
with WBRT [20]. Even with the better distant control of the addition of WBRT to 
SRS, the increase in morbidity does not outweigh the benefits and thus SRS alone is 
preferred.
Another viable option for limited brain metastases is surgical resection. Given 
similar outcomes in overall survival with surgical resection, decreased cost and, 
most importantly, less invasive nature of treatment compared to neurosurgery, SRS 
treatment of metastasis is being widely used [19, 21, 22].
The most common long term side effect of SRS is radionecrosis. While in certain 
cases radionecrosis can cause serious neurocognitive deficits requiring steroids or 
even surgical resection, certain patients remain asymptomatic and are diagnosed on 
imaging studies. Only about one third of patients with radionecrosis present with 
symptomatic neurologic deficits [23, 24]. Image based diagnoses can be difficult to 
distinguish from other phenomena including self-limiting inflammation [25]. There 
is a wide range of reported data on the rate of actuarial radionecrosis. In recent 
studies with adequate follow-up, rates vary from as low as 1.5% [26] to as high 34% 
[19, 25, 27] The main risk factor of radionecrosis are total dose, maximum tumor 
diameter and treated volume [25, 27, 28].
Given the variability in data and to help gain a better understanding of risk fac-
tors for radionecrosis, it may be salient to delineate the setting in which SRS is being 
administered. Prevalence of radionecrosis can be divided based on single fraction 
treatments, hypo fractionated treatments (usually three fractions), and adjuvant 
SRS after resection.
In patients receiving single fractionation SRS, the risk of radionecrosis are 
reported to be higher compared to hypofractionated [24]. Additionally, local 
control in hypofractionated regimens have had similar outcomes. Current NCCN 
guidelines recommend either single fraction or multi-fractionated SRS for the 
treatment of brain metastases, with multiple fractions utilized more commonly in 
patients with larger lesions [25, 29].
Not all patients radiologically diagnosed with radionecrosis are symptomatic. 
For patients that are symptomatic common manifestations include headache, 
seizures, motor deficits, sensory deficits, ataxia, and speech deficits [25].
In the past decade, SRS has more frequently been utilized in the post-resection 
adjuvant setting of brain metastases rather than WBRT. In hopes of optimizing 
local control and overall survival, SRS is administered to the tumor bed with the 
goal of covering subtotal resections and unrevealed disease that may have been left 
behind. In this setting, the prevalence of radionecrosis is varied with trends towards 
decreased toxicity with hypofractionated schedules compared to single fraction 
SRS [23, 26, 30]. The region of the brain being irradiated may have implications of 
morbidity as well. Infratentorial metastases are particularly problematic in that they 
portend worse outcomes and have a higher rate of radionecrosis [30]. Patients with 
higher risk of radionecrosis, including large tumors >3 cm, should be considered for 
hypofractionated treatment.
Another method of predicting radionecrosis in patients being treated with SRS 
is looking at volumes of brain parenchyma receiving a specific dose. Specifically, 
volumes receiving 10 Gy (V10) and 12 Gy (V12) have demonstrated strong pre-
dictive value in single fraction SRS [24, 25, 31]. The risk of radionecrosis can be 
predicted using specific volumes that receive certain doses. For example, risk of 
radionecrosis for V12 of less than 10 cm3 is 22% compared to more than 10 cm3 
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which more than doubles the risk to 55% [32]. Novel studies have proposed using 
V12 as the standard method of reporting dose to assess toxicity [25]. For patients 
receiving V12 of <8.5 cm3, the risk of radionecrosis increase to >10% and patients 
should be considered for hypofractionated rather than single fraction SRS [25].
Options in the treatment of radionecrosis includes steroids, hyperbaric oxygen, 
and surgery. There exist novel therapies such as bevacizumab and focused intersti-
tial laser thermal therapy with variable efficacy in treatment [33].
Stereotactic radiosurgery (SRS) is usually well-tolerated and risks of high grade 
toxicity are low. The most important sequelae of SRS is radiation necrosis. Risks and 
benefits must be weighed out on an individualized basis using an evidence based 
and patient centered approach.
5. Hypopituitarism induced by radiation
Endocrine deficiencies have also been reported in lesions irradiated near the 
hypothalamic-pituitary axis or pituitary gland. The prevalence of endocrinopathies 
are higher with nasopharyngeal cancers compared to intracerebral tumors, yet 
there were no differences in the rate of endocrine dysfunction based on underlying 
tumor type [34]. Endocrinopathies may include panhypopituitarism, hypothalamic 
hypothyroidism, and hypothalamic hypogonadism among others. A significant 
portion of the pediatric population treated with radiation therapy are vulnerable to 
pituitary dysfunction, most commonly growth hormone deficiency revealing short 
stature and retarded growth [35].
Patients with the pituitary adenomas are commonly treated with either single 
fraction SRS or hypofractionated SRS with similar rates of efficacy in tumor control 
and prevalence in new-onset hypopituitarism. Rates of hypopituitarism vary but 
are reported to be as high as 66% in conventional radiotherapy and significantly 
lower with stereotactic radiosurgery 5–37% [35–39].
Endocrine dysfunction is considered a late-delay side effect, but current litera-
ture is lacking in predicting a timeline for when hypopituitarism can occur. Follow 
up with dynamic serum hormonal values is of paramount importance given higher 
likelihood of developing endocrinopathies with longer follow up [35, 37].
6. Radiation induced optic neuropathy and stereotactic radiosurgery
Certain tumor types treated with SRS expose the optic nerves to high doses of 
radiation that may induce a decrease in visual acuity and blindness. Deterioration 
of vision may be reversible in an acute setting and is more likely to be permanent 
>6 months after treatment. Optic neuropathy from radiation is usually painless 
and can be monocular or biocular depending on whether optic nerves or the optic 
chiasm are exposed to radiation. Doses of radiation to optic nerves are closely 
monitored and circumvented as best as possible for patients receiving treatment for 
meningiomas, pituitary adenomas, and craniopharyngiomas.
Significant risk factors for radiation-induced optic neuropathy include prior 
radiation re-exposure to the optic chiasm. Prior EBRT and SRS are both risk fac-
tors for radiation induced optic neuropathy. Although multiple centers consider 
<8 Gy to be the upper limit of acceptable tolerability, single fractions of <12 Gy have 
been validated by recent literature [40–42]. A large recent analysis of pooled data 
consider the risk of radiation induced optic neuropathy to be 0–2% in patients with 
no prior irradiation to the optic apparatus and a single fraction <12 Gy [42] and 
even lower (<1%) for patients with a single fraction of <10 Gy [43].
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7. Toxicities of spinal cord irradiation
Radiation myelopathy is the term commonly used for side effects of radiation 
toxicity to the spinal cord. Late effects of radiation myelopathy are a serious concern 
for radiation oncologists during treatment planning of CNS as well as extra-neural 
tumors within the treatment field. This is, in part, due to higher doses of radiation 
required for certain tumors (lung, certain head and neck, mediastinal tumors). 
Moreover, metastatic disease to the spine often requires radiation therapy and is 
becoming more common thanks to the advent of immunotherapy [44]. Long term 
effects may cause life limiting sequelae and are of paramount concern to radiation 
planning and treatment.
Adverse facts of spinal cord irradiation are largely determined by the radiation 
treatment field and can affect both the central and peripheral nervous system. Just 
as side effects can be subdivided by timeframe in radiation toxicity to the brain, 
toxicities of spinal cord irradiation are classified as early toxicity, early-delayed 
effects, and long term effects. Accordingly, the durations are during treatment and 
up to a couple weeks after treatment, within 3 months of treatment, and more than 
3 months after treatment. Although acute central nervous system damage has been 
reported following acute brain irradiation, there is no clinical or experimental evi-
dence that radiation induces acute spinal cord toxicity. Single doses of up to 100 Gy 
have been given without acute effects [32].
Significant advances have been made in the treatment of spinal malignancies 
extrapolating progress made from cranial stereotactic techniques of within millime-
ter precision high dose focal treatment plans. Recently, SRS has also been utilized 
for metastasis to the spinal cord. It is important to note that metastasis to the spinal 
bone, although extremely painful at times, does not carry the risk of neurologic 
compromise posed by spinal cord tumors or spinal impingement.
Side effects using SRS are extremely rare for spinal tumors. Short-term toxicity 
although more common, are still at low rates and are usually self-limiting [45]. One 
study showed no long term side effects with SRS patients with spinal metastasis.
It seems as if long-term toxicity from radiation using SRS and dose sparing 
techniques to organs at risk is extremely rare with modern treatment techniques and 
attention to dose volume parameters. The complication of vertebral compression 
fracture (VCF) is multifactorial including older age portending to higher incidences 
osteoporosis but may be attributed to, in part, radiation therapy [46]. Doses above 
20 Gy in a single fraction have been implicated as a risk factor. The risk of VCF tends 
to occur in the acute period of toxicity [47].
The main factors associated with risk of neurologic deficit relate to total dose, 
length of spinal cord irradiated, fractionation scheme and total duration of treat-
ment. An absolute threshold for development of myelopathy cannot be stated. 
There has not been an established threshold; however the risk of myelopathy varies 
from 0.2 to 5% at 5 years [39]. Another side effects or radiation to the spine is 
characterized by acute paralysis presumably secondary to ischemia. Brown-Séquard 
syndrome is another rare syndrome that has been documented and is characterized 
by paralysis and loss of proprioception to the ipsilateral side and loss of pain and 
temperature to the contralateral side. Similar to irradiation to the brain, the greatest 
concern is delayed-onset radionecrosis of the spinal cord.
Common types of side effects for single dose SRS with 10–16 Gy include: neu-
rologic signs of motor weakness and sensory changes of the extremities [48]. There 
was no detectable acute or subacute radiation toxicity in this series noted clinically 
during the maximum follow-up time of 24 months. Other more disabling manifes-
tations of radiation injury, including acute paralysis secondary to ischemia, hemor-
rhage within the spinal cord, and a lower motor neuron syndrome, are much less 
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common, with only a few case reports in the literature. The treatment of radiation 
myelopathy has not been well studied. High dose corticosteroids are considered first 
line therapy.
8. Conclusions
Radiation therapy is highly effective in CNS malignancies. Nevertheless, the 
rate limiting step in treatment is associated with adverse side effects to healthy 
tissue. As the treatment of CNS malignancies advance with novel therapies and ever 
evolving therapeutic combinations, the goal of minimizing treatment side effects 
remains the same. Significant progress has been made in attempting to understand 
the dynamic mechanisms of brain injury caused by irradiation to healthy tissue. As 
patients continue to live longer, central nervous system side effects are of utmost 
importance to recognize and treat. Radiation oncologists among other cancer 
specialists are putting keen focus and effort towards increasing and optimizing 
quality-of-life in addition to overall survival in cancer patients.
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